(2010). Cherrez-Ojeda I: Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
(1999). DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J
(2010). Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report. [http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm],
(2011). Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention.[http://www.ginasthma.org/guidelines-gina-report-globalstrategy-for-asthma.html],
(2000). JE: Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol
(2000). JE: Mometasone furoate administered once daily is as effective as twicedaily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol
(2001). JE: Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol
(1994). LE: Determining a minimal important change in a disease-specific Quality of Life Questionnaire.
(2005). Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med
(1992). TK: Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax
(2010). Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc
(2010). Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc